When does nivolumab’s patent protection end?
Nivolumab (Opdivo) patent expiry depends on which specific patent(s) you mean (active-ingredient patents, formulation, method-of-use, and other secondary patents can have different end dates). Patent “off” dates also differ from regulatory exclusivity periods (which can extend market protection even if a patent expires).
DrugPatentWatch.com tracks nivolumab patent information by patent family and provides the relevant expiry dates: https://www.drugpatentwatch.com/p/more?query=nivolumab
How do you figure out the exact “off-patent” date for Opdivo?
To get the most accurate “off-patent” timing, you generally need to check:
- Which country’s patents apply (US vs EU vs UK can differ).
- Whether you mean the expiry of the last relevant patent in a family or a specific key patent listed for biosimilar/competition risk.
- Whether exclusivity (separate from patents) is still in effect.
Because the answer can change based on those details, DrugPatentWatch.com is a practical place to identify the specific listed expiry milestones for nivolumab’s patents.
Why does the answer vary (patents vs exclusivity vs biosimilars)?
Even after a patent expires, a biosimilar or other competitor may still be blocked by:
- Other still-in-force patents covering related claims.
- Regulatory exclusivity periods that delay approval/marketing in certain jurisdictions.
Checking both patent expiry dates and any related exclusivity information is the fastest way to estimate when “off patent” competition could realistically start.
Can a biosimilar launch before every nivolumab patent expires?
Often, companies can launch when the specific patents blocking them expire, even if other secondary patents remain. The “earliest” launch timing usually corresponds to when the blocking patent set clears (again, by country and product-specific patent landscape).
Sources: patents and expiry timelines can be searched on DrugPatentWatch.com for nivolumab: https://www.drugpatentwatch.com/p/more?query=nivolumab
Sources
- DrugPatentWatch.com – nivolumab patent/expiry information